Wave Life Sciences Ltd. (WVE) Research
Wave Life Sciences Ltd. (WVE) is a clinical-stage genetic medicine firm dedicated to inventing, refining, and manufacturing novel stereopure oligonucleotide therapies. The company utilizes its proprietary PRISM platform for discovery and drug development. These specialized oligonucleotides are designed to interact with ribonucleic acid (RNA) to precisely modulate protein expression within the body. This involves either diminishing the production of disease-causing proteins, restoring the synthesis of functional proteins, or generally adjusting protein levels as needed. The company's pipeline includes several key programs targeting neurological disorders. WVE-004, a C9orf72 molecule, is being developed for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). WVE-003 focuses on the mutant huntingtin SNP3 molecule for Huntington's disease, while WVE-N531 targets Exon 53 for Duchenne muscular dystrophy. Additionally, ATXN3 is an early-stage program addressing spinocerebellar ataxia 3, complemented by multiple other preclinical initiatives for central nervous system (CNS) conditions. Beyond CNS applications, Wave Life Sciences is also developing GalNAc-conjugated AIMers for various hepatic indications, including Alpha-1 antitrypsin deficiency (AATD). Their preclinical efforts extend to ocular diseases, with programs for Usher syndrome type 2A (USH2A) and retinitis pigmentosa caused by a P23H mutation in the RHO gene (RhoP23H). Wave Life Sciences actively collaborates with a diverse array of partners, such as pharmaceutical companies like Pfizer Inc. and Takeda Pharmaceutical Company Limited, alongside academic and research institutions including the University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A., University of Louisville, and University College London. Established in 2012, the company is headquartered in Singapore.
Market snapshot
- Symbol
- WVE
- Price
- $6.16
- Day change
- +3.53%
- Market cap
- $1.2B
- P/E ratio
- -6.72x
- 52-week range
- 5.02-21.73
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 1 month
- Analyst price target
- $20.29
Recent news
- Wave Life Sciences shares plummet on weight loss therapy update
Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE GalNAc-siRNA therapy, despite results showing improvements in body composition and continued safety and tolerability. The Phase 1 INLIGHT trial reported that a single 240 mg dose of WVE-007 produced placebo-adjusted reductions of 14.3% in visceral fat, 5% in total fat, a 2% increase in lean mass, a 3.3% reduction in waist circumference, and a 0.9% reduction in body weight after six months.
- Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?
At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizing lean mass with a 2% increase.
- Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints
Wave Life Sciences shares plunged over 55% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a dangerous type of belly fat.
Peer companies
Recent insider activity
- Wright Christopher I — trade (0 shares) on 2026-04-09
- Wright Christopher I — trade (300000 shares) on 2026-04-09
- Wright Christopher I — trade (273750 shares) on 2026-04-09
- Ingelsson Erik — trade (0 shares) on 2026-04-09
- Ingelsson Erik — trade (200000 shares) on 2026-04-09
Open Wave Life Sciences Ltd. (WVE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.